Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Pharma giant Pfizer and Bain Capital teamed up to launch Cerevel Therapeutics, a new biopharmaceutical company based in Boston that will focus on developing therapies to treat central nervous system disorders.
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
Myriad Genetics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib).
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
Two well-established pharma companies are expanding in two different U.S. cities. One city is known for the plethora of pharma and biotech jobs, while the other is in an area that might not immediately spring to mind when it comes to biotech hubs.
Myriad to Provide BRACAnalysis CDx Testing in a Phase 2 Study Evaluating Talazoparib for Neo-adjuvant Treatment of Germline BRCA-mutated Triple Negative Breast Cancer
Commercialization Plan Now in Place for BRACAnalysis CDx® As a Companion Diagnostic with Pfizer’s Talazoparib
As the timeline shortens for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has released details of the new senior management team that will continue to lead the company forward.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.